Alcon's VEGAMOX(TM) Ophthalmic Solution Approved in Japan for Eye Infections

VEGAMOX(TM) solution is a fourth-generation fluoroquinolone eyedrop formulated at a 0.5% concentration, providing high drugconcentration throughout relevant ocular structures. Its near-neutralpH of 6.8 provides for ocular comfort. In clinical studies,VEGAMOX(TM) solution has demonstrated excellent efficacy andtherapeutic penetration.

Alcon Japan President Scott Manning said the approval will presentan opportunity for increased sales in Japan, the world's secondlargest ocular anti-infective market.

"The approval of VEGAMOX(TM) solution provides Alcon Japan with animportant opportunity to expand its pharmaceutical offerings in Japanto include anti-infectives and more fully serve Japaneseophthalmologists," said Manning. "Because of its clinical profile andour experience with it in the U.S., where it is the number oneprescribed ocular anti-infective, as well as the strong preference forfluoroquinolones by Japanese ophthalmologists, we expect it to be astrong participant in the anti-infective market in Japan. Inanticipation of the commercial launch of VEGAMOX(TM) solution thisyear, we are expanding our sales force in order to reach physicianswith information about how this product may contribute to thetreatment of bacterial eye diseases."

VEGAMOX(TM) solution is currently approved as VIGAMOX(R) solutionin more than 40 countries around the world.

About Alcon

Alcon, Inc. (NYSE:ACL) is the world's leading eye care companywith sales of $4.4 billion in 2005. Alcon, which has been dedicated tothe ophthalmic industry for more than 50 years, develops, manufacturesand markets pharmaceuticals, surgical equipment and devices, contactslens care solutions and other vision care products that treatdiseases, disorders and other conditions of the eye. For moreinformation on Alcon, Inc., visit the Company's web site atwww.alconinc.com. Moxifloxacin hydrochloride ophthalmic solution 0.5 %is licensed to Alcon, Inc. by Bayer HealthCare, AG.

Caution Concerning Forward-Looking Statements. This press releasecontains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These statements involveknown and unknown risks, uncertainties and other factors which maycause our actual results, performance or achievements to be materiallydifferent from any future results, performances or achievementsexpressed or implied by our forward-looking statements. Thesestatements reflect the views of our management as of the date of thispress release with respect to future events and are based onassumptions and subject to risks and uncertainties. Given theseuncertainties, you should not place undue reliance on theseforward-looking statements.